Breaking News Headlines Today | Ground News

See every side of every news story

Pharmaceutical-technology.com image

News from pharmaceutical-technology.com

Ground News rates Pharmaceutical-technology.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Pharmaceutical-technology.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Pharmaceutical-technology.com

Where is Pharmaceutical-technology.com located?Pharmaceutical-technology.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pharmaceutical-technology.com News

Merck Tops Quarterly Estimates, Posts Modest 2026 Guidance as Generic Competition Looms

Merck Tops Quarterly Estimates, Posts Modest 2026 Guidance as Generic Competition Looms

Coverage: 6 sources

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition.See the Story

What's Going On With Aquestive Therapeutics Stock Today? - Aquestive Therapeutics (NASDAQ:AQST)

United States · United States

What's Going On With Aquestive Therapeutics Stock Today? - Aquestive Therapeutics (NASDAQ:AQST)

100% Center coverage: 2 sources

On Monday, Aquestive Therapeutics, Inc. (NASDAQ:AQST) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of Anaphylm (dibutepinephrine) Sublingual Film for Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more (approximately 66 pounds). In January, the FDA identified deficiencies in Anaphylm's NDA that preclude discussion o…See the Story

Genentech, SanegeneBio Launch Up-to-$1.7B RNAi Collaboration

Genentech, SanegeneBio Launch Up-to-$1.7B RNAi Collaboration

Genentech, a member of the Roche Group, will apply SanegeneBio’s RNA interference (RNAi) platform to develop one of the company’s RNAi programs through a global licensing agreement that could generate up to $1.5 billion for the Chinese biotech. Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program. SanegeneBio agreed to oversee early development activities while Gen…See the Story

Breaking News Topics Related to Pharmaceutical-technology.com